Literature DB >> 18312286

Sickle cell disease status and outcomes of African-American men presenting with priapism.

Nelson Bennett1, John Mulhall2.   

Abstract

INTRODUCTION: Priapism is associated with sickle cell disease (SSD); however, few men receive education about this condition, which contributes to attenuated return of functional erections. AIM: To define the demographics, SSD status, and treatment outcomes of African-American men presenting with priapism. MAIN OUTCOME MEASURES: Demographics, medical history, self-report of sickle cell status, and outcome assessment using International Inventory of Erectile Function (IIEF) of men with priapism were retrospectively reviewed.
METHODS: A review of 39 cases of venocclusive priapism in African-American men was conducted. Charts were reviewed for demographics, medical history including SSD status by patient self-report, serum hemoglobin electrophoresis results, and priapism treatment and outcome.
RESULTS: Mean duration of presenting priapism episode was 22 +/- 12 hours (6-70 hours). Eight percent of men had priapism for <12 hours, 59% 12-24 hours, 22% 24-36 hours, and 11% >36 hours. All patients with priapism events of >12 hours complained of reduction in erectile rigidity. No patients with priapism >36 hours duration had return of spontaneous functional erections, but 44% (24-36 hours), 78% (12-24 hours) and 100% (<12 hours) were able to generate functional erections with or without the use of sildenafil. Follow-up IIEF erectile function domain scores paralleled incidence of functional erections. Penile shunt surgery was required in 28%. Only 5% of men recalled learning that priapism was a complication of SSD. Six men denied a history of SSD; however, hemoglobin electrophoresis revealed abnormal hemoglobin S and elevated hemoglobin F levels in four of these men.
CONCLUSIONS: The association of SSD and venocclusive priapism is well known in the medical community, yet few patients ever receive education regarding the emergency nature of the condition. The majority of men presents in a delayed fashion, and a significant proportion requires shunt surgery leading to long-term erectile dysfunction. Of those who denied having SSD, two-thirds had SSD by hemoglobin electrophoresis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312286     DOI: 10.1111/j.1743-6109.2008.00770.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  22 in total

1.  Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.

Authors:  Arthur L Burnett; Uzoma A Anele; Irene N Trueheart; John J Strouse; James F Casella
Journal:  Am J Med       Date:  2014-03-25       Impact factor: 4.965

Review 2.  Evaluation and management of priapism: 2009 update.

Authors:  Yun-Ching Huang; Ahmed M Harraz; Alan W Shindel; Tom F Lue
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

3.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

Review 4.  Medical management of ischemic stuttering priapism: a contemporary review of the literature.

Authors:  Helen R Levey; Omer Kutlu; Trinity J Bivalacqua
Journal:  Asian J Androl       Date:  2011-11-07       Impact factor: 3.285

5.  Excess adenosine A2B receptor signaling contributes to priapism through HIF-1α mediated reduction of PDE5 gene expression.

Authors:  Chen Ning; Jiaming Wen; Yujin Zhang; Yingbo Dai; Wei Wang; Weiru Zhang; Lin Qi; Almut Grenz; Holger K Eltzschig; Michael R Blackburn; Rodney E Kellems; Yang Xia
Journal:  FASEB J       Date:  2014-03-10       Impact factor: 5.191

Review 6.  Management of priapism: an update for clinicians.

Authors:  Helen R Levey; Robert L Segal; Trinity J Bivalacqua
Journal:  Ther Adv Urol       Date:  2014-12

Review 7.  Priapism in sickle-cell disease: a hematologist's perspective.

Authors:  Gregory J Kato
Journal:  J Sex Med       Date:  2011-05-06       Impact factor: 3.802

Review 8.  [Priapism: Current diagnostics and therapy].

Authors:  B Schwindl; T Bschleipfer; T Klotz
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

9.  The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient Outcomes through Respect and Trust study.

Authors:  Shawn M Bediako; Sophie Lanzkron; Marie Diener-West; Gladys Onojobi; Mary C Beach; Carlton Haywood
Journal:  J Health Psychol       Date:  2014-07-04

10.  Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism.

Authors:  Jiaming Wen; Xianzhen Jiang; Yingbo Dai; Yujin Zhang; Yuxin Tang; Hong Sun; Tiejuan Mi; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  J Sex Med       Date:  2010-09       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.